Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 https://t.co/lFXl2ywbZe #ACR22 @RheumNow
Links:
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib …
http://bit.ly/3hFhZ0n
14-11-2022